Leading the charge

Delivering on the promise of nocions™

Press releases

May 5, 2026
Nocion Therapeutics Announces Full Enrollment in Phase 2b ASPIRE Study of Taplucainium for Chronic Cough
PDF version
April 1, 2026
Nocion Therapeutics Strengthens Board of Directors with Appointment of Mark Iwicki
PDF version
January 26, 2026
Nocion Therapeutics to Present Preclinical Data Supporting Nocions™ as a Novel Approach for the Treatment of Pain at the Non-Opioid Pain Therapeutics Summit
PDF version
January 7, 2026
Nocion Therapeutics Extends Series B Financing to $93 Million to Support Late-Stage Development of Taplucainium in Chronic Cough
PDF version
April 28, 2025
Nocion Therapeutics Appoints Matthew Frankel, M.D., MBA to Chief Medical Officer
PDF version
November 18, 2024
Nocion Therapeutics Announces First Patient Dosed in ASPIRE Phase 2b Chronic Cough Study
PDF version
July 15, 2024
Nocion Therapeutics Presents Data on Preclinical and Clinical Development of Taplucainium, a Novel, Charged Sodium Channel Blocker, as a potential treatment for Chronic Cough at the 13th London International Cough Symposium
PDF version
July 8, 2024
Nocion Therapeutics Appoints Dr. Catherine Bonuccelli to Scientific Advisory Board and Joan Shaw to Senior Vice President, Clinical Operations
PDF version
April 2, 2024
Lumira Ventures Announces Investment in Nocion Therapeutics to Revolutionize Chronic Cough Treatment
PDF version
March 4, 2024
Nocion Therapeutics Announces $62 Million Series B Financing to Advance Lead Program in Cough into Later Stage Developmen
PDF version
August 31, 2021
Nocion Therapeutics Announces Dosing Underway in Participants with Chronic Cough
PDF version
September 1, 2020
Nocion Therapeutics Advances to Clinical Stage and Expands Leadership.
PDF version
NOVEMBER 18, 2019
Nocion Therapeutics identifies lead clinical candidate for refractory chronic cough and expands the management team
PDF version
SEPTEMBER 23, 2019
FierceBiotech names Nocion Therapeutics as one of its “Fierce 15” Biotech Companies of 2019
PDF version
APRIL 17, 2019
Nocion Therapeutics launches to selectively silence pain and itch neurons
PDF version

News coverage

March 4, 2024
By Endpoints
March 4, 2024
By Boston Business Journal
August 26, 2021
By The University of Manchester
July 16, 2020
By Fierce Biotech
September 23, 2019
By Fierce Biotech